Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Warittakorn Kategeaw, Nontaya Nakkam, Sasisopin Kiertiburanakul, Chonlaphat Sukasem, Wichittra Tassaneeyakul & Nathorn Chaiyakunapruk. (2023) Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand. Journal of Medical Economics 26:1, pages 1330-1341.
Read now
Read now
Unchalee Permsuwan, Voratima Yoodee, Wacin Buddhari, Nattawut Wongpraparut, Tasalak Thonghong, Sirichai Cheewatanakornkul, Krissada Meemook, Pranya Sakiyalak, Pongsanae Duangpakdee & Jirawit Yadee. (2022) Cost–Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand. ClinicoEconomics and Outcomes Research 14, pages 487-498.
Read now
Read now
Natthakan Chitpim, Jiraphun Jittikoon, Wanvisa Udomsinprasert, Surakameth Mahasirimongkol & Usa Chaikledkaew. (2022) Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand. ClinicoEconomics and Outcomes Research 14, pages 61-73.
Read now
Read now
Ziping Ye, Jia Ma, Fuyao Liu, Chen Wang, Ziyang Zhou & Lihua Sun. (2022) A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 53-61.
Read now
Read now
André Soares Santos, Augusto Afonso Guerra-Junior, Brian Godman, Alec Morton & Cristina Mariano Ruas. (2018) Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Review of Pharmacoeconomics & Outcomes Research 18:3, pages 277-288.
Read now
Read now
David Cameron, Jasper Ubels & Fredrik Norström. (2018) On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Global Health Action 11:1.
Read now
Read now
Unchalee Permsuwan, Piyameth Dilokthornsakul, Kednapa Thavorn, Surasak Saokaew & Nathorn Chaiyakunapruk. (2017) Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. Journal of Medical Economics 20:2, pages 171-181.
Read now
Read now
Leath Al Obaidi & Jörg Mahlich. (2015) A potential gender bias in assessing quality of life – a standard gamble experiment among university students. ClinicoEconomics and Outcomes Research 7, pages 227-233.
Read now
Read now
Asrul Akmal Shafie, Yen Wei Lim, Gin Nie Chua & Mohammed Azmi Ahmad Hassali. (2014) Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia. ClinicoEconomics and Outcomes Research 6, pages 473-481.
Read now
Read now
Articles from other publishers (45)
Yared Belete Belay, Lidia Engel, Yong Yi Lee, Ngoc Le & Cathrine Mihalopoulos. (2023) Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review. PharmacoEconomics 41:6, pages 651-673.
Crossref
Crossref
Olivier Bruyère, Johann Detilleux & Jean-Yves Reginster. (2023) Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand. Medicines 10:3, pages 23.
Crossref
Crossref
Piyameth Dilokthornsakul, Ratree Sawangjit, Manathip Osiri, Praveena Chiowchanwisawakit, Worawit Louthrenoo & Unchalee Permsuwan. (2023) Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand. Value in Health Regional Issues 34, pages 40-47.
Crossref
Crossref
Jirawit Yadee, Unchalee Permsuwan, Kansinee Guntawongwan, Woraluck Himakalasa & Piyaluk Buddhawongsa. (2023) Discounting money and health effects from communicable and noncommunicable diseases in Thailand. Scientific Reports 13:1.
Crossref
Crossref
Siwaporn Niyomsri, Mantiwee Nimworapan, Wanwarang Wongcharoen & Piyameth Dilokthornsakul. (2023) Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis. International Journal of Environmental Research and Public Health 20:4, pages 3176.
Crossref
Crossref
Yashika Chugh, Gaurav Jyani, Mayur Trivedi, Sandra Albert, Sitanshu Sekhar Kar, Binod Patro, Swati Raman, Kavitha Rajsekar, Rachel Mairi Baker, Cam Donaldson & Shankar Prinja. (2023) Protocol for estimating the willingness-to-pay-based value for a quality-adjusted life year to aid health technology assessment in India: a cross-sectional study. BMJ Open 13:2, pages e065591.
Crossref
Crossref
Hossein Safari, Thomas G. Poder, Somayeh Afshari, Azin Nahvijou, Morteza Arab-Zozani, Nasrin Moradi & Hosein Ameri. (2022) Determination of a cost-effectiveness threshold for cancer interventions in Iran. Frontiers in Oncology 12.
Crossref
Crossref
Wanrudee Isaranuwatchai, Ryota Nakamura, Hwee Lin Wee, Myka Harun Sarajan, Yi Wang, Budsadee Soboon, Jing Lou, Jia Hui Chai, Wannisa Theantawee, Jutatip Laoharuangchaiyot, Thanakrit Mongkolchaipak, Thanisa Thathong, Pritaporn Kingkaew, Kriang Tungsanga & Yot Teerawattananon. (2022) What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand. PLOS ONE 17:10, pages e0274944.
Crossref
Crossref
Krittimeth Trerayapiwat, Peerawat Jinatongthai, Prin Vathesatogkit, Piyamitr Sritara, Ninutcha Paengsai, Piyameth Dilokthornsakul, Surakit Nathisuwan, Lan My Le & Nathorn Chaiyakunapruk. (2022) Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand. The Lancet Regional Health - Western Pacific 26, pages 100503.
Crossref
Crossref
Rungroj Krittayaphong & Unchalee Permsuwan. (2022) Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. American Journal of Cardiovascular Drugs 22:5, pages 577-590.
Crossref
Crossref
Piyameth Dilokthornsakul, Ratree Sawangjit, Pisit Tangkijvanich, Maneerat Chayanupatkul, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Pajaree Sriuttha & Unchalee Permsuwan. (2022) Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand. Applied Health Economics and Health Policy 20:4, pages 587-596.
Crossref
Crossref
Nathorn Chaiyakunapruk, Dayoung Song, Julia Lynch, Jerome H. Kim, Piyameth Dilokthornsakul, Tawee Chotpitayasunondh & Vittal Mogasale. (2022) Public Health Value of a Hypothetical Pneumococcal Conjugate Vaccine (PCV) Introduction: A Case Study. Vaccines 10:6, pages 950.
Crossref
Crossref
Haru Iino, Masayuki Hashiguchi & Satoko Hori. (2022) Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. PLOS ONE 17:4, pages e0266934.
Crossref
Crossref
Joseph Kazibwe, Adrian Gheorghe, David Wilson, Francis Ruiz, Kalipso Chalkidou & Y-Ling Chi. (2022) The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review. Value in Health 25:3, pages 385-389.
Crossref
Crossref
Kriengsak Vareesangthip, Chaicharn Deerochanawong, Dittaya Thongsuk, Nuch Pojchaijongdee & Unchalee Permsuwan. (2022) Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Advances in Therapy 39:3, pages 1279-1292.
Crossref
Crossref
Christian R. C. Kouakou & Thomas G. Poder. (2021) Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. The European Journal of Health Economics 23:2, pages 277-299.
Crossref
Crossref
Jumpol Singhirunnusorn, Siwaporn Niyomsri & Piyameth Dilokthornsakul. (2022) The cost-effectiveness analysis of laparoscopic hepatectomy compared with open liver resection in the early stage of hepatocellular carcinoma: a decision-analysis model in Thailand. HPB 24:2, pages 183-191.
Crossref
Crossref
Seyedeh-Fariba Jahanbin, Hasan Yusefzadeh, Bahram Nabilou & Cyrus Alinia. (2021) Value of willingness to pay for a QALY gained in Iran; a modified chained-approach. BMC Health Services Research 21:1.
Crossref
Crossref
Mac Ardy Junio Gloria, Montarat Thavorncharoensap, Usa Chaikledkaew, Sitaporn Youngkong, Ammarin Thakkinstian & Anthony J. Culyer. (2021) A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain. Value in Health 24:10, pages 1423-1434.
Crossref
Crossref
Rungroj Krittayaphong & Unchalee Permsuwan. (2021) Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand. Clinical Drug Investigation 41:10, pages 907-915.
Crossref
Crossref
Rungroj Krittayaphong & Unchalee Permsuwan. (2021) Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International Journal of Cardiology 322, pages 183-190.
Crossref
Crossref
Khachen Kongpakwattana & Nathorn Chaiyakunapruk. (2020) Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer’s Disease Treatment Using Real-World Evidence in Thailand. Value in Health 23:6, pages 710-718.
Crossref
Crossref
Piyameth Dilokthornsakul, Surakit Nathisuwan, Rungroj Krittayaphong, Aurauma Chutinet & Unchalee Permsuwan. (2020) Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. Heart, Lung and Circulation 29:3, pages 390-400.
Crossref
Crossref
Jürgen John, Florian Koerber & Mareike Schad. (2019) Differential discounting in the economic evaluation of healthcare programs. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
Khachen Kongpakwattana, Zanfina Ademi, Thanaputt Chaiyasothi, Surakit Nathisuwan, Ella Zomer, Danny Liew & Nathorn Chaiyakunapruk. (2019) Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. PharmacoEconomics 37:10, pages 1277-1286.
Crossref
Crossref
Najme Moradi, Arash Rashidian, Shirin Nosratnejad, Alireza Olyaeemanesh, Marzieh Zanganeh & Leila Zarei. (2019) The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. PharmacoEconomics - Open 3:3, pages 311-319.
Crossref
Crossref
Piyameth Dilokthornsakul, Kirati Kengkla, Surasak Saokaew, Unchalee Permsuwan, Chonnamet Techasaensiri, Tawee Chotpitayasunondh & Nathorn Chaiyakunapruk. (2019) An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine 37:32, pages 4551-4560.
Crossref
Crossref
Ithiphon Viratanapanu, Chavalit Romyen, Komol Chaivanijchaya, Sikarin Sornphiphatphong, Worawit Kattipatanapong, Ajjana Techagumpuch, Krit Kitisin, Suppa-ut Pungpapong, Chadin Tharavej, Patpong Navicharern, Patchaya Boonchayaanant & Suthep Udomsawaengsup. (2019) Cost-Effectiveness Evaluation of Bariatric Surgery for Morbidly Obese with Diabetes Patients in Thailand. Journal of Obesity 2019, pages 1-6.
Crossref
Crossref
Rungroj Krittayaphong & Unchalee Permsuwan. (2018) Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. American Journal of Cardiovascular Drugs 18:5, pages 405-413.
Crossref
Crossref
Praveen Thokala, Jessica Ochalek, Ashley A. Leech & Thaison Tong. (2018) Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 36:5, pages 509-522.
Crossref
Crossref
A. Mavrodi, V. Aletras, A. Spanou & D. Niakas. (2017) Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity. PharmacoEconomics - Open 1:4, pages 291-300.
Crossref
Crossref
Surachai Kotirum, Charung Muangchana, Sirirat Techathawat, Piyameth Dilokthornsakul, David Bin-Chia Wu & Nathorn Chaiyakunapruk. (2017) Economic Evaluation and Budget Impact Analysis of Vaccination against Haemophilus influenzae Type b Infection in Thailand. Frontiers in Public Health 5.
Crossref
Crossref
Yen Wei Lim, Asrul Akmal Shafie, Gin Nie Chua & Mohammed Azmi Ahmad Hassali. (2017) Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia. Value in Health 20:8, pages 1131-1138.
Crossref
Crossref
Patricia Coelho De Soarez & Hillegonda Maria Dutilh Novaes. (2017) Limiares de custo-efetividade e o Sistema Único de Saúde. Cadernos de Saúde Pública 33:4.
Crossref
Crossref
Melanie Y BertramJeremy A LauerKees De JoncheereTessa EdejerRaymond HutubessyMarie-Paule KienySuzanne R Hill. (2016) Cost–effectiveness thresholds: pros and cons. Bulletin of the World Health Organization 94:12, pages 925-930.
Crossref
Crossref
Laura Vallejo-Torres, Borja García-Lorenzo, Iván Castilla, Cristina Valcárcel-Nazco, Lidia García-Pérez, Renata Linertová, Elena Polentinos-Castro & Pedro Serrano-Aguilar. (2016) On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?. Value in Health 19:5, pages 558-566.
Crossref
Crossref
Unchalee Permsuwan, Nathorn Chaiyakunapruk, Piyameth Dilokthornsakul, Kednapa Thavorn & Surasak Saokaew. (2016) Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. Applied Health Economics and Health Policy 14:3, pages 281-292.
Crossref
Crossref
Khachapon Nimdet & Surachat Ngorsuraches. (2015) Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open 5:10, pages e008123.
Crossref
Crossref
Linda Ryen & Mikael Svensson. (2015) The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature. Health Economics 24:10, pages 1289-1301.
Crossref
Crossref
Ruth Schwarzer, Ursula Rochau, Kim Saverno, Beate Jahn, Bernhard Bornschein, Nikolai Muehlberger, Magdalena Flatscher-Thoeni, Petra Schnell-Inderst, Gaby Sroczynski, Martina Lackner, Imke Schall, Ansgar Hebborn, Karl Pugner, Andras Fehervary, Diana Brixner & Uwe Siebert. (2015) Systematic overview of cost–effectiveness thresholds in ten countries across four continents. Journal of Comparative Effectiveness Research 4:5, pages 485-504.
Crossref
Crossref
Lan Gao, Li Xia, Song-Qing Pan, Tao Xiong & Shu-Chuen Li. (2015) Health-Related Quality of Life and Willingness to Pay per Quality-Adjusted Life-Year Threshold—A Study in Patients with Epilepsy in China. Value in Health Regional Issues 6, pages 89-97.
Crossref
Crossref
Khachapon Nimdet, Nathorn Chaiyakunapruk, Kittaya Vichansavakul & Surachat Ngorsuraches. (2015) A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?. PLOS ONE 10:4, pages e0122760.
Crossref
Crossref
Durga Bista, Leanne Chalmers, Luke Bereznicki & Gregory Peterson. (2014) Potential use of NOACs in developing countries: pros and cons. European Journal of Clinical Pharmacology 70:7, pages 817-828.
Crossref
Crossref
Yot Teerawattananon, Nattha Tritasavit, Netnapis Suchonwanich & Pritaporn Kingkaew. (2014) The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 108:7, pages 397-404.
Crossref
Crossref
Lisa A. Robinson & James K. Hammitt. (2018) Valuing Nonfatal Health Risk Reductions in Global Benefit‐Cost Analysis. SSRN Electronic Journal.
Crossref
Crossref